Tonghuashun (300033) Financial Research Center, April 12cryptorockstarSome investors asked Watson Biotech (300142)(300142). The company's share price continued to fall. The company's research stated that 9-valent HPV is already in the stage of writing a clinical report. Since it is the stage of writing a clinical report, then the head-to-head core data of neutralizing antibodies must be out. Can you publish simple core data?
The company replied, Dear Investor, Hello! In early February, the company obtained preliminary results of a head-to-head clinical trial of the company's nine-valent HPV vaccine and similar vaccines, showing that the vaccine has good safety and immunogenicity. Among them, the antibody positive conversion rate of 4 types is 100%, the antibody positive conversion rate of 4 types is 99%, and the antibody positive conversion rate of 1 type is 91%. The company is currently based on the clinical development plan of 9-valent HPV products, maintain close communication with CDE, and actively strive to promote clinical research on protective effectiveness with optimal strategies. Thank you!
